This discussion with Dr Paul Russo presents a case for cytoreductive nephrectomy, despite the results from the CARMENA trial, which did not show an overall survival advantage. The report concludes that careful selection of patients with intermediate-risk (not poor-risk) metastatic renal cell carcinoma (RCC) and cytoreductive nephrectomy performed by experienced surgeons, followed by treatment with […]
Around 12,500 new cases of renal cell carcinoma (RCC) are diagnosed annually in the UK, and about a third of these cases initially present with cancer that has spread to other parts of the body (non-localised or metastatic). Non-localised RCC has significantly worse 5-year survival outcomes compared with localised disease. The treatment options for patients […]
In this video clip, Professor Eric Jonasch, Medical Oncologist, Division of Cancer Medicine at MD Anderson Cancer Center, University of Texas, Houston, speaks about the role of cytoreductive surgery along with immunotherapy for patients who have metastatic renal cell carcinoma (RCC). Watch the video on Practice Update here
The results of this open-label pilot study were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. The study investigated the use of neoadjuvant (before surgery) immunotherapy in patients with metastatic renal cell carcinoma (RCC). One hundred and five patients with metastatic RCC were randomised to receive […]
The results from CARMENA, a randomised phase III clinical trial to assess the importance of surgery to remove the kidney (nephrectomy) in people with metastatic kidney cancer, have been re-analysed and were presented at the 2019 American Society of Clinical Oncology (ACSO) annual meeting in Chicago this week. The original results showed that many people with […]
The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an […]
The following survey assessed patient views related to cytoreductive nephrectomy following publication of the results of the CARMENA trial, and were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The survey found that overall survival should not be overestimated as the most important aim […]
The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from surgeon Dr Paul Russo, Memorial Sloan Kettering Cancer […]
Results of the phase 3 SURTIME trial comparing pretreatment with sunitinib before nephrectomy, with immediate nephrectomy followed by sunitinib treatment were published in JAMA Oncology recently. The findings suggest that pretreating metastatic renal cell carcinoma (RCC) patients with sunitinib before surgery may lead to better or at least similar outcomes for patients compared to immediate nephrectomy. Although […]
This review paper was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week. Results from the CARMENA study were reviewed and recommendations made for cytoreductive nephrectomy for people with advanced renal cell carcinoma (RCC). CARMENA is a randomised clinical trial comparing patients who had […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
